natgillin/translations-raw huggingface dataset:
The computer-readable medium of claim 8 wherein the step of adding the compensation signal to a control signal to form a qd control signal comprises the step of adding the compensation signal to a Vqse synchronous frame voltage command in the motor drive system (100). 
Računalno čitljivi medij u skladu s patentnim zahtjevom 8, naznačen time što korak dodavanja kompenzacijskog signala u kontrolni signal da se formira qd kontrolni signal obuhvaća korak dodavanja kompenzacijskog signala u Vqse naredbu napona sinkronog okvira u sustavu pogona motora (100).
Combination comprising cabazitaxel, which may be in the form of anhydrous base, a hydrate or a solvate, and cisplatin, said combination to be for an administration of cabazitaxel by perfusion at a dose from 15 to 25 mg/m2 and for administration of cisplatin by perfusion at a dose of 75 mg/m2, for its use for the treatment of cancer. 
Kombinacija koja sadrži kabazitaksel, koji može biti u obliku bezvodne baze, hidrata ili solvata, i cisplatin, navedena kombinacija je za primjenu kabazitaksela perfuzijom u dozi od 15 do 25 mg/m2 i za primjenu cisplatina perfuzijom u dozi od 75 mg/m2, naznačena time što za uporabu za liječenje raka.
Combination for the use according to claim 1, where cabazitaxel is in the form of a solvate. 
Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što je kabazitaksel u obliku solvata.
Combination for the use according to claim 1, where the cycle of administration of the two antitumoral agents is repeated with an interval between two administrations of cabazitaxel of three weeks. 
Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što se ciklus davanja dvaju antitumorskih sredstava ponavlja s razmakom od tri tjedna između dva davanja kabazitaksela.
Combination for the use according to claim 1, where the amount of cabazitaxel represents from 10 to 90% by weight of the combination. 
Kombinacija za uporabu prema patentnom zahtjevu 1, naznačena time što količina kabazitaksela predstavlja od 10 do 90 masenih % kombinacije.
A pharmaceutical kit, which comprises: 
Farmaceutski komplet, koji sadrži:
A pharmaceutical kit for the use according to claim 11, where the cycle of administration of the two antitumoral agents is repeated with an interval between two administrations of cabazitaxel of three weeks. 
Farmaceutski komplet za uporabu u skladu sa zahtjevom 11, naznačen time što se ciklus davanja dvaju antitumorskih sredstava ponavlja s razmakom od tri tjedna između dva davanja kabazitaksela.
The method according to claim 25, wherein the diafiltration is performed by circulating the composition through a hollow fiber cartridge comprising a cut-off value in the range of 10-50 kDa, and with a surface area in the range of 0.05-1 m2, and with a cartridge inlet pressure in the range of 70-280 kPa, until one to seven volumes of buffer exchange have taken place. 
Postupak in vitro prema zahtjevu 13, naznačen time, da se diafiltracija provodi putem cirkuliranja sastava kroz šuplju vlaknastu filtersku patronu koja obuhvaća minimalnu razlikovnu vrijednost u rasponu od 10 – 50 kDa, gdje je površinsko područje u rasponu od 0,05 – 1 m2, te s patronskim ulaznim tlakom u rasponu od 70 – 280 kPa, sve dok se ne provede od jednoga do sedam volumena puferske izmjene.
The method according to claim 1, wherein the total concentration of first homodimeric and second homodimeric antibodies in step a) is at least 0.25 mg/mL. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da ukupna koncentracija od prvog protutijela pune duljine i drugog protutijela pune duljine u koraku a) iznosi najmanje 0,25 mg/mL.
The operation method according to claim 9, further comprising, starting from the average relative height, for a significant passage duration of the cutting unit over the root, increasing the relative height, and for an average duration, keeping the relative height, and for a shorter duration, reducing then relative height. 
Postupak rada prema zahtjevu 9 ili prema zahtjevima 9 i 10, naznačen time, što, počevši od prosječne relativne visine (H), povećava navedenu relativnu visinu za značajno trajanje prolaska jedinice za rezanje preko korijena (2), dok zadržava navedenu relativnu visinu za prosječno trajanje, te smanjuje navedenu relativnu visinu za kraće trajanje.
An apparatus according to claim 3, wherein the coil core is constructed from a soft magnetic material. 
Brojilo hitaca prema patentnom zahtjevu 3, naznačeno time, da je jezgra zavojnice izrađena iz mekog magnetskog materijala, osobito iz mekog željeza.
An apparatus according to claim 1, further including a processor, wherein the coil is configured to provide the processor (54) at least with a portion of the voltage induced in the coil. 
Brojilo hitaca prema jednom od prethodnih patentnih zahtjeva, naznačeno time, da da nadalje sadrži procesor (54), kod čega je zavojnica (1) konstruirana da procesoru (54) pribavlja barem dio napona induciranog u zavojnici.
An apparatus according to claim 8, wherein the processor is configured to identify and count a fired shot when an amplitude of the induced voltage passes a threshold level and/or a course of the induced voltage corresponds to a predetermined form. 
Brojilo hitaca prema patentnom zahtjevu 8, naznačeno time, da je procesor (54) konstruiran da prepozna i pribroji ispaljeni hitac kada visina induciranog napona prelazi vrijednost praga i/ili tok induciranog napona odgovara predodređenom obliku.
An apparatus according to claim 9, wherein the processor is configured to use a portion of the induced voltage provided, to supply operating power. 
Brojilo hitaca prema jednom od patentnih zahtjeva 8 ili 9, naznačeno time, da je procesor (54) konstruiran tako da koristi dio njemu pripremljenog induciranog napona za opskrbu pogonskom energijom.
based on the form of the induced voltages, especially the amplitude, deciding whether a shot was fired, and when a shot was fired, incrementing a shooting score. 
odlučivanje, bazirajući se na obliku, osobito amplitudi induciranih napona, da li je hitac bio prethodno ispaljen ili ne, i kada je hitac bio ispaljen, o porastu broja hitaca.
A method of producing the pharmaceutical composition of claim 6, comprising mixing a compound according to formula 1 with one or more inert fillers and/or solvents. 
Metoda za proizvodnju farmaceutske kompozicije prema patentnom zahtjevu 12 preko miješanja spojeva koje je prikazano formulom 1 prema patentnom zahtjevu 1 sa inertnim puniocem i/ili otapalom.
The compound according to claim 5 for use for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis, lupus erythematodes, lupus nephritis and allergic rhinoconjunctivitis. 
Spoj za uporabu u liječenju bolesti u skladu s patentnim zahtjevom 30, naznačen time, da je bolest odabrana iz skupine koja se sastoji od astme, KOPB-a, alergijskog rinitisa, sindroma opasnog respiratornog poremećaja kod odraslih, bronhitisa, alergijskog dermatitisa, kontaktnog dermatitisa, idiopatske trombocitopenijske purpure, reumatoidnog artritisa, lupus eritematode, lupus nefritisa i alergijskog rinokonjunktivitisa.
Pharmaceutical formulations, characterised in that they contain one or more compounds according to one of claims 1 to 6 in combination with an active substance selected from the group consisting of anticholinergics, betamimetics, corticosteroids, PDE4-inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, CRTH2-antagonists,HMG-CoA reductase inhibitors and NSAIDs. 
Farmaceutski pripravci, naznačeni time, da oni sadrže jedan ili više spojeva u skladu s jednim od patentnih zahtjeva 1 do 27 u kombinaciji s djelatnom tvari odabranom iz skupine koja se sastoji od antikolinergika, betamimetika, kortikosteroida, PDE4-inhibitora, EGFR-inhibitora, LTD4-antagonista, CCR3-inhibitora, iNOS-inhibitora, CRTH2-antagonista, inhibitora reduktaze HMG-CoA i NSAID-a.
is selected from the group consisting of methyl and ethyl; 
je odabran iz skupine koja se sastoji od metila i etila;
is selected from the group consisting of C6-10-aryl, Het and Hetaryl; 
je odabran iz skupine koja se sastoji od sljedećih: -10-aril, Het i Hetaril;
OH, oxo, -CN, halogen, -C1-6-alkyl, -O-C1-6-alkyl, -C1-6-haloalkyl, three- to seven-membered cycloalkyl, Het, Hetaryl, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkylene)-O-(C1-3-alkyl), -O- Het, which is optionally further substituted by one, two or three substituents X, whereby each X is selected from the group consisting of halogen, oxo, -C1-4-alkyl, -O-C1-4-alkyl, -C1-4-haloalkyl, -O-(C1-4-alkylene)- Het, Het, Hetaryl, -NH2, whereby substituent X is optionally further substituted by one, two or three substituents of a group selected from oxo, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl, and the pharmaceutically acceptable salts of the aforementioned compounds. 
OH, okso, -CN, halogen, -C1-6-alkil, -O-C1-6-alkil, -C1-6-haloalkil, tročlani do sedam-člani cikloalkil, Het, Hetaril, -CO-N(CH3)2, -CO-NHCH3, -CO-NH2, -(C1-3-alkilen)-O-(C1-3-alkil), O-Het, koji je opcionalno dalje supstituiran s jednim, dva ili tri supstituenta X, pri čemu je svaki X odabran iz skupine koja se sastoji od sljedećih: halogen, okso, -C1-4-alkil, -O-C1-4-alkil, -C1-4-haloalkil, -O-(C1-4-alkilen)-Het, Het, Hetaril, -NH2, pri čemu je supstituent X opcionalno dalje supstituiran s jednim, dva ili tri supstituenta iz skupine odabrane od okso, metila, etila, n-propila, izopropila, n-butila, izobutila i tert-butila, i farmaceutski prihvatljive soli od gore spomenutih spojeva.
The compound of formula 1a according to claim 1 or of formula 1a ' according to claim 2, wherein is selected from the group consisting of phenyl, Het and Hetaryl; 
Spoj formule 1a u skladu s patentnim zahtjevom 1, ili formule 1a’ u skladu s patentnim zahtjevom 2, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: fenil, Het i Hetaril;
either selected from the group consisting of Het and Hetaryl; 
ili odabran iz skupine koja se sastoji od Heta i Hetarila;
The compound of formula 1a or of formula 1a ' according to claim 4, wherein R 1 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiophenyl, furanyl, pyrazolopyridinyl, indazolyl, thiazolyl, imidazo-pyridinyl and indolyl, wherein this R 1 -residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is optionally further substituted by one, two or three substituents Z, whereby each Z is a substituent selected from the group consisting of 
Spoj formule 1a ili formule 1a’ prema patentnom zahtjevu 4, naznačen time, da je odabran iz skupine koja se sastoji od piridinila, pirimidinila, pirazinila, pirolila, imidazolila, pirazolila, tiofenila, furanila, pirazolopiridinila, indazolila, tiazolila, imidazo-piridinila i indolila, gdje je taj R1 –ostatak priključen na preostali dio molekule bilo putem C-atoma ili putem N-atoma i opcionalno je dalje supstituiran s jednim, dva ili tri supstituenta Z, pri čemu je svaki Z supstituent odabran iz skupine koja se sastoji od sljedećih:
The compound of formula 1a or of formula 1a ' according to claim 4, which is selected from the group consisting of and and the pharmaceutically acceptable salts of the aforementioned compounds. 
Spoj formule 1a ili formule 1a’ prema patentnom zahtjevu 4, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: i farmaceutski prihvatljive soli od gore spomenutih spojeva.
A pharmaceutically acceptable salt of any of the compounds of claims 10, 11, 12, 13, 14 or 15. 
Farmaceutski prihvatljiva sol, naznačena time, da je od bilo kojeg od spojeva iz patentnih zahtjeva 11, 12, 13, 14 ili 15.
The compound of formula 1c according to claim 1 or of formula 1c' according to claim 2 wherein is selected from the group consisting of phenyl, Het and Hetaryl; 
Spoj formule 1c prema patentnom zahtjevu 1 ili formule 1c’ u skladu s patentnim zahtjevom 2 naznačen time, da je odabran iz skupine koja se sastoji od sljedećih: fenil, Het i Hetaril;
The compound of formula 1c or of formula 1c' according to claim 17, wherein R1 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, thiophenyl, furanyl, pyrazolopyridinyl, indazolyl, thiazolyl, imidazo-pyridinyl and indolyl, wherein this R1 -residue is attached to the rest of the molecule either via a C-atom or via an N-atom and is optionally further substituted by one, two or three substituents Z, whereby each Z is a substituent selected from the group consisting of 
Spoj formule 1c ili formule 1c’ prema patentnom zahtjevu 17, naznačen time, da je odabran iz skupine koja se sastoji od piridinila, pirimidinila, pirazinila, pirolila, imidazolila, pirazolila, tiofenila, furanila, pirazolopiridinila, indazolila, tiazolila, imidazo-piridinila i indolila, gdje je taj R1 –ostatak priključen na preostali dio molekule bilo putem C-atoma ili putem N-atoma i opcionalno je dalje supstituiran s jednim, dva ili tri supstituenta Z, pri čemu je svaki Z supstituent odabran iz skupine koja se sastoji od sljedećih:
An intermediate compound selected from the group consisting of formula 6 of formula 7 of formula 8 and of formula 11 wherein R1 is defined as in claim 1 and wherein Hal is Cl or Br and wherein X is -B(OH)2, -boronic acid pinacolester, -trifluoroborate or -SnBu3 and wherein PG is a protecting group selected from the group consisting of benzyl, 1-phenylethyl, 1-(4-methoxyphenyl)ethyl. 
Intermedijaran spoj, naznačen time, da je odabran iz skupine koja se sastoji od formule 6 formule 7 formule 8 i formule 11 gdje R1 je definiran isto kao u patentnom zahtjevu 1 i gdje Hal je Cl ili Br, i gdje X je -B(OH)2, -pinakolester borne kiseline, -trifluoroborat ili -SnBu3, i gdje PG je zaštitna skupina odabrana iz skupine koja se sastoji od benzila, 1-feniletila, 1-(4-metoksifenil)etila.
The compound for use for the treatment of a disease according to claim 30, wherein this disease is selected from the group consisting of asthma, COPD, allergic rhinitis, adult respiratory distress syndrome, bronchitis, allergic dermatitis, contact dermatitis, idiopathic thrombocytopenic purpura, rheumatoid arthritis, lupus erythematodes, lupus nephritis and allergic rhinoconjunctivitis. 
Spoj za uporabu u liječenju bolesti u skladu s patentnim zahtjevom 30, naznačen time, da je bolest odabrana iz skupine koja se sastoji od astme, KOPB-a, alergijskog rinitisa, sindroma opasnog respiratornog poremećaja kod odraslih, bronhitisa, alergijskog dermatitisa, kontaktnog dermatitisa, idiopatske trombocitopenijske purpure, reumatoidnog artritisa, lupus eritematode, lupus nefritisa i alergijskog rinokonjunktivitisa.
The compound for use for the treatment of a disease according to one of claims 30 or 31, wherein the disease is selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis. 
Spoj za uporabu u liječenju bolesti u skladu s jednim od patentnih zahtjeva 30 ili 31, naznačen time, da je bolest odabrana iz skupine koja se sastoji od astme, KOPB-a, alergijskog rinitisa, alergijskog dermatitisa, lupus eritematode, lupus nefritisa i reumatoidnog artritisa.
the heavy chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence at least 90% identical thereto, and wherein the light chain variable domain comprises a CDR3 region comprising the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence at least 85% identical thereto, and wherein the antibody or the antigen-binding portion thereof is capable of inhibiting cancer growth in a mammal, or ii) the binding is binding to a conformational or discontinuous epitope on human GDF-15 comprised by the amino acid sequences of SEQ ID No: 25 and SEQ ID No: 26, and wherein the antibody or the antigen-binding portion thereof is capable of inhibiting cancer growth in a mammal. 
varijabilna domena teškog lanca obuhvaća regiju CDR3 koja sadrži sekvencu aminokiselina SEQ ID NO: 5 ili aminokiselinsku sekvencu koja je najmanje 90% identična s tim, i gdje varijabilna domena lakog lanca sadrži regiju CDR3 koja sadrži sekvencu aminokiselina SEQ ID NO: 7 ili s njima najmanje 85% identična aminokiselinska sekvenca, i gdje antitijelo ili njegov dio koji veže antigen može inhibirati rast raka kod sisavca, ili ii) vezanje se veže na konformacijski ili diskontinuirani epitop na humanom GDF-15 koji se sastoji od aminokiselinskih sekvenci SEQ ID NO: 25 i SEQ ID NO: 26, i gdje je antitijelo ili njegov dio koji veže antigen sposoban za inhibiranje rasta raka kod sisavaca.
The monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein the mammal is a human patient. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 1, naznačeno time, da je sisavac ljudski pacijent.
The monoclonal antibody or antigen-binding portion thereof of any one of claims 1-4, wherein the antibody or antigen-binding portion thereof is an antibody or antigen-binding portion thereof according to claim 1 i), and wherein the binding is binding to a conformational or discontinuous epitope on human GDF-15. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno bilo kojem od patentnih zahtjeva 1-4, naznačeno time, da antitijelo ili njegov dio koji se veže za antigen je antitijelo ili njegov dio koji se veže za antigen sukladno zahtjevu 1 i), i gdje je vezanje vezivo na konformacijski ili diskontinuirani epitop na humanom GDF-15.
The monoclonal antibody or antigen-binding portion thereof of any one of claims 1 to 6, wherein the antibody or antigen-binding portion thereof has an equilibrium dissociation constant for human GDF-15 that is equal to or less than 5 nM as measured by surface plasmon resonance measurements. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno bilo kojem od zahtjeva 1 do 6, naznačen time, da antitijelo ili njegov dio koji veže antigen ima konstantu ravnoteže disocijacije za humani GDF-15 koja je jednaka ili manja od 5 nM kako je izmjereno mjerenjima površinske plazmonske rezonancije.
The monoclonal antibody or antigen-binding portion thereof of any one of claims 1 to 7, wherein the antibody or antigen-binding portion thereof has an equilibrium dissociation constant for human GDF-15 that is equal to or less than 2 nM as measured by surface plasmon resonance measurements. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno bilo kojem od zahtjeva 1 do 7, naznačen time, da antitijelo ili njegov dio koji veže antigen ima konstantu ravnoteže disocijacije za ljudski GDF-15 koja je jednaka ili manja od 2 nM kako je izmjereno mjerenjima površinske plazmonske rezonancije.
The monoclonal antibody or antigen-binding portion thereof of claim 7 or 8, wherein the equilibrium dissociation constant is as measured by surface plasmon resonance measurements according to Example 1. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 7 ili 8, naznačeno time da je ravnotežna konstanta disocijacije izmjerena mjerenjima površinske plazmonske rezonance u skladu s Primjerom 1.
The antibody or antigen-binding portion thereof or the pharmaceutical composition according to claim 11 for the use according to claim 11, wherein the mammal is a human patient. 
Antitijelo ili njegov dio koji se veže za antigen ili farmaceutski pripravak sukladno zahtjevu 11 za uporabu sukladno zahtjevu 11, naznačen time, što je sisavac ljudski pacijent.
A kit comprising the pharmaceutical composition of claim 10. 
Komplet koji sadrži farmaceutski sastav sukladno zahtjevu 10.
A composition for use according to claim 1 wherein the adherent-invasive Escherichia coli strain is present in one or more of the intestinal parts (small and large) of the subject. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu je prijanjajuće-invazivni soj Escherichije coli prisutan u jednom ili više dijelova crijeva (tankog ili debelog) subjekta.
A composition for use according to claim 1 wherein the adherent-invasive Escherichia coli strain is LF82, 07081, 07082, 07076 or 06075. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu je prijanjajuće-invazivni soj Escherichije coli LF82, 07081, 07082, 07076 ili 06075.
A composition for use according to any one of claims 1 to 3 wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis or recurrence of ileal lesions after surgery, for example surgery for the removal of at least a part of the small intestine in CD patients. 
Spoj za uporabu sukladno bilo kojem od patentnih zahtjeva od 1 do 3, pri čemu kronična upalna bolest crijeva je Chronova bolest ili ulcerozni kolitis ili ponavljanje crijevnih lezija nakon operacije, na primjer operacija odstranjivanja barem jednog dijela tankog crijeva kod Chronovih bolesnika.
A composition for use according to any one of claims 1 to 4 wherein the composition is for oral administration. 
Spoj za uporabu sukladno bilo kojem od patentnih zahtjeva od 1 do 4, pri čemu je spoj oralne primjene.
Tray according to claim 1, wherein said lid (4) is mounted on the external part of said perimeter wall (3). 
Ladica prema patentnom zahtjevu 1, gdje je navedeni poklopac (4) montiran na vanjski dio navedenog obodnog zida (3).
Tray according to claim 1, wherein said extension module (10) comprises protrusions (7) that are housed inside complementary holes (8) provided in a lower extension module or in the base module (9). 
Ladica prema patentnom zahtjevu 1, gdje navedeni modul (10) za proširenje sadrži izbočine (7) koje su smještene unutar komplementarnih rupa (8) koje su predviđene u donjem modulu za proširenje ili u osnovnom modulu (9).
A compound of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: 
Spoj formule (I): ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljiva sol, pri čemu:
is independently selected from: C1-5 alkyl substituted with 0-3 Re; C1-5 alkenyl, and C1-6 cycloalkyl; provided when R2 is C1-5 alkyl, the carbon atom except the one attached directly to the pyridine ring may be replaced by O and S; is independently selected from: 
je nezavisno odabrano od: C1-5 alkil supstituiran sa 0-3 Re; C2-5 alkenil, i C3-6 cikloalkil; pod uvjetom da kada R2 je C1-5alkil, atom ugljika izuzev onog vezanog direktno za piridin prsten može biti zamijenjen sa O i S; je nezavisno odabrano od:
R6a is independently selected from: H, CH3, aryl substituted with 0-3 Re, and heterocyclyl substituted with 0-3 Re; 
a je nezavisno odabrano od: H, CH3, aril supstituiran sa 0-3 Re, i heterociklil supstituiran sa 0-3 Re;
Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 Re, wherein the heterocyclic ring is selected from: 
Ra i Ra zajedno sa atomom dušika za koji su oba vezana formiraju heterociklični prsten supstituiran sa 0-5 Re, pri čemu heterociklični prsten je odabran od:
is independently selected from: 
je nezavisno odabrano od:
A compound selected from the group consisting of: 
Spoj u skladu sa patentnim zahtjevom 1 odabrano iz grupe koja se sastoji od:
A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of any one of claims 1-11, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof. 
Farmaceutska kompozicija, koja sadrži farmaceutski prihvatljiv nosač i spoj iz bilo kojeg od patentnih zahtjeva 1-21, ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljivu sol.
The TCR of any preceding claim having an alpha chain TRAC constant domain sequence and/or a beta chain TRBC1 or TRBC2 constant domain sequence. 
TCR sukladno patentnom zahtjevu 1 koji ima TRAC sekvencu konstantne domene alfa lanca i/ili TRBC1 ili TRBC2 sekvencu konstantne domene beta lanca.
The TCR or cell for use of claim 17, for use in a method of treating cancer. 
TCR ili stanica za uporabu sukladno patentnom zahtjevu 13, za upotrebu u postupku za liječenje raka.
a controller (124, 224) configured to: 
timer (248) i kontroler (124, 224) konfigurirane za: